Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer

Franca De Paola, Anna Maria Granato, Emanuela Scarpi, Franco Monti, Laura Medri, Simonetta Bianchi, Dino Amadori, Annalisa Volpi

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) has emerged as one of the most important angiogenic growth factors from experimental in vitro and in vivo studies. In the present study, we investigated the relationship between VEGF expression and microvessel density (MVD) and defined their prognostic relevance on a series of 242 patients with node-negative breast cancer, using immunohistochemical methods. In parallel, estrogen and progesterone receptors were quantitatively assessed using the dextran-charcoal technique and cell proliferation was evaluated as S-phase cell fraction according to 3H-thymidine-labeling index (TLI). The percentage of VEGF-expressing cells varied from 0-95% in the different tumors and was unrelated to menopausal status, tumor size or steroid receptor status. Conversely, a significant inverse relation was observed with patient age or tumor cell proliferation, albeit with very poor correlation coefficients. A significant relation was observed between VEGF expression and MVD (rs = 0.55, p <0.001). Clinical outcome analyzed as a function of high and low VEGF expression showed slight differences in terms of both disease-free survival (DFS) and overall survival (OS) that never reached statistical significance. Moreover, the trend was paradoxically in favor of patients with highly VEGF-expressing tumors. Finally, DFS and OS curves, when analyzed as a function of VEGF expression or MVD, were superimposable. In conclusion, our study did not highlight a prognostic relevance of VEGF expression in patients with node-negative breast cancer, as already observed for MVD.

Original languageEnglish
Pages (from-to)228-233
Number of pages6
JournalInternational Journal of Cancer
Volume98
Issue number2
DOIs
Publication statusPublished - Mar 10 2002

Fingerprint

Vascular Endothelial Growth Factor A
Breast Neoplasms
Microvessels
Disease-Free Survival
Neoplasms
Cell Proliferation
Survival
Steroid Receptors
Angiogenesis Inducing Agents
Charcoal
Progesterone Receptors
Dextrans
S Phase
Estrogen Receptors
Thymidine
Intercellular Signaling Peptides and Proteins

Keywords

  • Breast cancer
  • Immunohistochemistry
  • MVD
  • Prognosis
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. / De Paola, Franca; Granato, Anna Maria; Scarpi, Emanuela; Monti, Franco; Medri, Laura; Bianchi, Simonetta; Amadori, Dino; Volpi, Annalisa.

In: International Journal of Cancer, Vol. 98, No. 2, 10.03.2002, p. 228-233.

Research output: Contribution to journalArticle

De Paola, F, Granato, AM, Scarpi, E, Monti, F, Medri, L, Bianchi, S, Amadori, D & Volpi, A 2002, 'Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer', International Journal of Cancer, vol. 98, no. 2, pp. 228-233. https://doi.org/10.1002/ijc.10118
De Paola, Franca ; Granato, Anna Maria ; Scarpi, Emanuela ; Monti, Franco ; Medri, Laura ; Bianchi, Simonetta ; Amadori, Dino ; Volpi, Annalisa. / Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. In: International Journal of Cancer. 2002 ; Vol. 98, No. 2. pp. 228-233.
@article{0617189aeaab47ae877414e49d354bcd,
title = "Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer",
abstract = "Vascular endothelial growth factor (VEGF) has emerged as one of the most important angiogenic growth factors from experimental in vitro and in vivo studies. In the present study, we investigated the relationship between VEGF expression and microvessel density (MVD) and defined their prognostic relevance on a series of 242 patients with node-negative breast cancer, using immunohistochemical methods. In parallel, estrogen and progesterone receptors were quantitatively assessed using the dextran-charcoal technique and cell proliferation was evaluated as S-phase cell fraction according to 3H-thymidine-labeling index (TLI). The percentage of VEGF-expressing cells varied from 0-95{\%} in the different tumors and was unrelated to menopausal status, tumor size or steroid receptor status. Conversely, a significant inverse relation was observed with patient age or tumor cell proliferation, albeit with very poor correlation coefficients. A significant relation was observed between VEGF expression and MVD (rs = 0.55, p <0.001). Clinical outcome analyzed as a function of high and low VEGF expression showed slight differences in terms of both disease-free survival (DFS) and overall survival (OS) that never reached statistical significance. Moreover, the trend was paradoxically in favor of patients with highly VEGF-expressing tumors. Finally, DFS and OS curves, when analyzed as a function of VEGF expression or MVD, were superimposable. In conclusion, our study did not highlight a prognostic relevance of VEGF expression in patients with node-negative breast cancer, as already observed for MVD.",
keywords = "Breast cancer, Immunohistochemistry, MVD, Prognosis, VEGF",
author = "{De Paola}, Franca and Granato, {Anna Maria} and Emanuela Scarpi and Franco Monti and Laura Medri and Simonetta Bianchi and Dino Amadori and Annalisa Volpi",
year = "2002",
month = "3",
day = "10",
doi = "10.1002/ijc.10118",
language = "English",
volume = "98",
pages = "228--233",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer

AU - De Paola, Franca

AU - Granato, Anna Maria

AU - Scarpi, Emanuela

AU - Monti, Franco

AU - Medri, Laura

AU - Bianchi, Simonetta

AU - Amadori, Dino

AU - Volpi, Annalisa

PY - 2002/3/10

Y1 - 2002/3/10

N2 - Vascular endothelial growth factor (VEGF) has emerged as one of the most important angiogenic growth factors from experimental in vitro and in vivo studies. In the present study, we investigated the relationship between VEGF expression and microvessel density (MVD) and defined their prognostic relevance on a series of 242 patients with node-negative breast cancer, using immunohistochemical methods. In parallel, estrogen and progesterone receptors were quantitatively assessed using the dextran-charcoal technique and cell proliferation was evaluated as S-phase cell fraction according to 3H-thymidine-labeling index (TLI). The percentage of VEGF-expressing cells varied from 0-95% in the different tumors and was unrelated to menopausal status, tumor size or steroid receptor status. Conversely, a significant inverse relation was observed with patient age or tumor cell proliferation, albeit with very poor correlation coefficients. A significant relation was observed between VEGF expression and MVD (rs = 0.55, p <0.001). Clinical outcome analyzed as a function of high and low VEGF expression showed slight differences in terms of both disease-free survival (DFS) and overall survival (OS) that never reached statistical significance. Moreover, the trend was paradoxically in favor of patients with highly VEGF-expressing tumors. Finally, DFS and OS curves, when analyzed as a function of VEGF expression or MVD, were superimposable. In conclusion, our study did not highlight a prognostic relevance of VEGF expression in patients with node-negative breast cancer, as already observed for MVD.

AB - Vascular endothelial growth factor (VEGF) has emerged as one of the most important angiogenic growth factors from experimental in vitro and in vivo studies. In the present study, we investigated the relationship between VEGF expression and microvessel density (MVD) and defined their prognostic relevance on a series of 242 patients with node-negative breast cancer, using immunohistochemical methods. In parallel, estrogen and progesterone receptors were quantitatively assessed using the dextran-charcoal technique and cell proliferation was evaluated as S-phase cell fraction according to 3H-thymidine-labeling index (TLI). The percentage of VEGF-expressing cells varied from 0-95% in the different tumors and was unrelated to menopausal status, tumor size or steroid receptor status. Conversely, a significant inverse relation was observed with patient age or tumor cell proliferation, albeit with very poor correlation coefficients. A significant relation was observed between VEGF expression and MVD (rs = 0.55, p <0.001). Clinical outcome analyzed as a function of high and low VEGF expression showed slight differences in terms of both disease-free survival (DFS) and overall survival (OS) that never reached statistical significance. Moreover, the trend was paradoxically in favor of patients with highly VEGF-expressing tumors. Finally, DFS and OS curves, when analyzed as a function of VEGF expression or MVD, were superimposable. In conclusion, our study did not highlight a prognostic relevance of VEGF expression in patients with node-negative breast cancer, as already observed for MVD.

KW - Breast cancer

KW - Immunohistochemistry

KW - MVD

KW - Prognosis

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0037051094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037051094&partnerID=8YFLogxK

U2 - 10.1002/ijc.10118

DO - 10.1002/ijc.10118

M3 - Article

C2 - 11857413

AN - SCOPUS:0037051094

VL - 98

SP - 228

EP - 233

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -